Table 2.
Association between BRM promoter polymorphism and UADT cancers.
| BRM polymorphism | Cases, n (%) | Controls, n (%) | Adjusted OR (95% CI)1; P-value |
|---|---|---|---|
| All cancers | n = 562 | n = 993 | |
| Wild type (reference) | 87 (15) | 205 (21) | 1 |
| Heterozygote (for either variant) | 296 (53) | 512 (52) | 1.38 (1.0–1.8) |
| BRM-741 homozygote only | 58 (10) | 97 (10) | 1.45 (0.9–2.2) |
| BRM-1321 homozygote only | 66 (12) | 114 (11) | 1.39 (0.9–2.1) |
| BRM-741 and-1321 homozygotes | 55 (10) | 65 (7)2 | 2.46 (1.7–3.8) |
| Lung cancer | n = 261 | n = 436 | |
| Wild type (reference) | 39 (15) | 91 (21) | 1 |
| Heterozygote (for either variant) | 137 (52) | 223 (51) | 1.45 (0.9–2.4) |
| BRM-741 homozygote only | 28 (11) | 45 (10) | 1.48 (0.9–2.9) |
| BRM-1321 homozygote only | 30 (11) | 48 (11) | 1.47 (0.8–2.7) |
| BRM-741 and-1321 homozygotes | 27 (10)2 | 29 (7) | 2.61 (1.5–4.9) |
| Esophageal cancer | n = 113 | n = 155 | |
| Wild type (reference) | 20 (18) | 30 (19) | 1 |
| Heterozygote (for either variant) | 59 (52) | 83 (54) | 1.07 (0.5–2.2) |
| BRM-741 homozygote only | 10 (9) | 13 (8) | 1.15 (0.4–3.6) |
| BRM-1321 homozygote only | 14 (12) | 18 (12) | 1.18 (0.4–3.3) |
| BRM-741 and-1321 homozygotes | 10 (9) | 11 (7) | 1.66 (0.7–5.8) |
| Head and neck cancer | n = 188 | n = 402 | |
| Wild type (reference) | 28 (15) | 84 (21) | 1 |
| Heterozygote (for either variant) | 100 (53) | 206 (51) | 1.46 (1.0–2.4) |
| BRM-741 homozygote only | 20 (11) | 39 (10) | 1.55 (0.7–3.2) |
| BRM-1321 homozygote only | 22 (12) | 48 (12) | 1.42 (0.7–3.1) |
| BRM-741 and-1321 homozygotes | 18 (10)2 | 25 (6) | 2.75 (1.4–5.6) |
BRM, Brahma; OR, odds ratio; CI, confidence interval; UADT, upper aerodigestive tract.
1
The OR was adjusted for: age, sex, smoking status, pack-years, and family history of UADT cancers.
2
Percentages do not add up to 100% due to rounding.